Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - kevin+dalby
2
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Covalent ERK inhibitors for suppressing cancer
BI-78D3, a small molecule, covalently binds to ERK1/2’s D-recruitment site, disrupting ERK signaling crucial for cancer cell growth. This shows promise for treating ERK-dependent cancers, including those resistant to BRAF inhibitors. This disrupts ERK signaling crucial for cell proliferation and survival, particularly in certain cancers like...
Published: 11/8/2024
|
Inventor(s):
Kevin Dalby
,
Ramakrishna Edupuganti
,
Tamer Kaoud
,
Chelsea Massaro
Keywords(s):
Category(s):
Life sciences > Therapeutics > Drug delivery
,
Life sciences > Therapeutics
Targeting MELK with indolinone derivatives
A promising strategy for treating triple-negative breast cancer and glioblastoma Indolinone derivatives inhibit MELK, an enzyme linked to cancer cell cycle regulation, proliferation, and apoptosis. These inhibitors show promise in treating cancers like triple-negative breast cancer and glioblastoma by selectively targeting MELK, reducing cancer cell...
Published: 9/11/2024
|
Inventor(s):
Kevin Dalby
,
Ramakrishna Edupuganti
Keywords(s):
Category(s):
Life sciences > Therapeutics > Formulation